

Investigator	Investigator's Site	Abstract #	Abstract Title	Medium	Authorship	Poster No.
Dr. Ehab El-Bahesh	Clearview Cancer Institute	e15574	Early operative management versus nonoperative care for cancer-associated small bowel obstruction in patients with recent peritoneal metastasis: A real-world propensity-matched analysis.	Publication		
Dr. Nicholas Iannotti	Hematology Oncology Associates of the Treasure Coast	2655	The differentiated SIRP α -IgG4 Fc fusion protein HCB101 in monotherapy and combination therapy.	Poster		445
Dr. Lasika Seneviratne	Los Angeles Cancer Network	1572	Achieving epidemiologically representative enrollment and social determinants of health in the phase III evERA Breast Cancer study (NCT05306340).	Poster		490
Dr. Victor Lin	Mary Bird Perkins Cancer Center	8570	1L olomorasib plus pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.	Poster		360
Dr. Richard Zuniga	New York Cancer & Blood Specialists	TPS4263	TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.	Poster		234a
Dr. Lawrence Garbo	New York Oncology Hematology	TPS4263	TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.	Poster		234a

Dr. Richard Zuniga	New York Cancer & Blood Specialists	3146	BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Exploratory pharmacodynamic (PD) and biomarker analyses from CA240-0007.	Poster		283
Dr. Makenzi Evangelist	New York Oncology Hematology	e20731	Clinical factors driving use of RET inhibitor pralsetinib and associated real-world outcomes in RET fusion-positive NSCLC: A retrospective chart review.	Publication	First Author	
Dr. Davey Daniel	Tennessee Oncology	1571	National implementation of electronic patient-reported outcomes (ePROs) for remote symptom monitoring in oncology: The OncoPRO initiative.	Poster		489
Dr. Ian Flinn	Tennessee Oncology	7046	Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.	Poster		544
Dr. Ian Flinn	Tennessee Oncology	7029	Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.	Poster	First Author	527
Dr. Jeffery Russell	Tennessee Oncology	2629	Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients	Poster		419

			with advanced malignancies post checkpoint inhibition.			
Dr. Jeffery Russell	Tennessee Oncology	TPS2665	ASP2998, a trophoblast cell-surface antigen 2 (TROP2)-targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study.	Poster		455a
Dr. Jeffery Russell	Tennessee Oncology	TPS3177	Beamion BCGC-1: Four new phase 1b/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC).	Poster		303a
Dr. Katy Beckermann	Tennessee Oncology	TPS11202	A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.	Poster		183b
Dr. Katy Beckermann	Tennessee Oncology	4550	Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease-associated neoplasms.	Poster		29
Dr. Katy Beckermann	Tennessee Oncology	4555	Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC).	Poster		34

Dr. Katy Beckermann	Tennessee Oncology	e16565	Clinical outcomes of muscle-invasive and metastatic, bladder, and urethral pure adenocarcinoma (BUAdenoCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).	Publication		
Dr. Katy Beckermann	Tennessee Oncology	e13672	Feasibility assessment of a global, anonymized, human-in-the-loop AI decision-support platform for oncology second opinions following a live demo at an international symposium.	Publication		
Dr. Brian Grieb	Tennessee Oncology	TPS4264	TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.	Poster		234a
Dr. Wade Iams	Tennessee Oncology	TPS8662	Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.	Poster		450b
Dr. Wade Iams	Tennessee Oncology	TPS8671	Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.	Poster		455a
Dr. Wade Iams	Tennessee Oncology	8613	COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results.	Poster		403

Dr. Wade Iams	Tennessee Oncology	8614	COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR-mutated advanced NSCLC: Interim results.	Poster		403
Dr. Wade Iams	Tennessee Oncology	e23121	Frameworks for improving comprehensive biomarker testing in NSCLC: A multi-stakeholder consensus.	Publication		